To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with
3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due
to the sequelae of atherosclerotic cardiovascular disease in older men and women.